For anyone aged 65 or older who is losing strength, or caring for someone who is: what a review of drug trials says about whether medicines can do the work of exercise, and why muscle on a scan is not the same as function.
Researchers from Japan, Singapore and the United States pooled 26 randomised controlled trials with 3,237 people aged 65 and over that tested medicines for sarcopenia, the age-related loss of muscle mass and function. The gains in function were small: hormonal and anabolic drugs added about 1 kg of grip strength and about 12 metres on a six-minute walk compared with the control groups. The review by Tsutsumi, Huang and colleagues was published online on 4 November 2026 in the journal Metabolism.
More muscle on a scan is not the same as more strength
Drug trials in sarcopenia often report a change in muscle mass or in selected functional tests. The authors set out to check how consistent those effects are and whether they are large enough to matter to a patient. They searched MEDLINE and Embase up to 9 February 2026, sorted the medicines into four broad therapeutic groups (hormonal and anabolic therapies, myostatin inhibitors, drugs acting on the renin–angiotensin system, and metabolic therapies) and compared function and body composition against the control arms of each trial.
What the pooled numbers show
Hormonal and anabolic therapies: grip strength higher by 1.0 kg (95% CI 0.007 to 2.0) and six-minute walk distance longer by 12.3 m (95% CI 5.0 to 19.6).
Myostatin inhibitors, drugs that block a protein which limits muscle growth: walking speed faster by 0.03 m per second; lean mass in the arms and legs was reported in a single trial (standardised difference 0.57).
Drugs acting on the renin–angiotensin system and metabolic therapies: estimates rested on few trials and varied from one outcome to another.
The authors write that every functional difference was below commonly cited benchmarks for a meaningful change, and that evidence for individual drug classes was sparse, with several classes represented by a single trial.
Where exercise stands
The international ICFSR guidelines on sarcopenia, published in 2018, strongly recommend resistance-based physical activity as treatment, conditionally recommend protein supplementation or a protein-rich diet, and give no recommendation for anabolic hormones because the evidence was not strong enough. The new review did not test exercise, so it cannot compare drugs with training directly. What it shows is that, years after that guideline, drug trials in older adults have still not produced a functional gain of the size the authors count as meaningful.
Where the evidence stops
This is a meta-analysis of trials of different medicines, and several drug classes rest on one trial each; the abstract does not describe how the trials differed in duration or in how sarcopenia was defined. The results are pooled group averages, and the abstract gives no data on how individual people responded. Changes in body composition were reported as standardised differences rather than in kilograms. The published summary does not report pooled results for falls, independence or side effects; the authors call for future trials built around durable mobility, independence and safety. Two authors hold roles at a biotech company, LiverGENIX, which the authors state had no part in the review. The full text was not available to us, so this article is based on the published abstract.
What to discuss with your doctor
For treating sarcopenia, the ICFSR guidelines strongly recommend resistance-based physical activity and conditionally recommend protein supplements or a protein-rich diet. If you notice a weaker grip or slower walking after 65, whether this is sarcopenia and whether any medicine has a place in your case is worth discussing with your doctor.
This article is for information only and does not replace a consultation with a doctor.
Sources
Tsutsumi T, Hieda S, Gnanavelou M, et al. Functional and body composition outcomes of pharmacological interventions for sarcopenia in older adults: A systematic review and pairwise meta-analysis of randomized controlled trials. Metabolism, 2026, published online 4 November. PubMed 42982100, doi:10.1016/j.metabol.2026.156820
Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging, 2018;22(10):1148–1161. PubMed 30498820
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchMedicine and treatmentA mineral supplement extended life in male mice by about 7%
A careful reading of early longevity research starts with what was measured, who was studied and what remains untested. This article separates a mouse finding from a decision about human health.
ResearchMedicine and treatmentEarly artery procedures added no years, lifting saved muscle: four studies
4 stories this week: stable coronary disease, keeping muscle while losing weight on medication, fatty liver with scarring and high triglycerides. What each trial measured, and where its evidence stops.
Digest · 4 stories
ResearchSleepInsomnia with sleep apnoea: what online therapy changed in a trial
For people who sleep badly and also have breathing pauses at night: what a blinded trial of clinician-guided online therapy changed, the weeks when sleepiness rose, and what it does not replace.